156 related articles for article (PubMed ID: 3329965)
1. Cefoperazone-sulbactam combination in the treatment of urinary tract infections: efficacy, safety, and effects on coagulation.
Greenberg RN; Reilly PM; Weinandt WJ; Bollinger M; Kennedy DJ
Clin Ther; 1987; 10(1):52-6. PubMed ID: 3329965
[TBL] [Abstract][Full Text] [Related]
2. [Laboratory and clinical study of sulbactam/cefoperazone (SBT/CPZ) on bacterial prostatitis].
Suzuki K; Horiba M
Hinyokika Kiyo; 1991 Oct; 37(10):1333-43. PubMed ID: 1755429
[TBL] [Abstract][Full Text] [Related]
3. [Clinical study on sulbactam/cefoperazone in urinary tract infections in elderly patients].
Oyabu Y
Jpn J Antibiot; 1996 Mar; 49(3):250-5. PubMed ID: 8935120
[TBL] [Abstract][Full Text] [Related]
4. Sulbactam/cefoperazone versus cefotaxime for the treatment of moderate-to-severe bacterial infections: results of a randomized, controlled clinical trial.
Li JT; Lu Y; Hou J; Chen YF; Miao JZ; Jia YX; Hou J; Zhang XZ; Chen DK; Hu WZ; Li LJ; Liu DM; Wang Z; Wu J; Gu JM; Wang HL; Zhang YL; Sun L
Clin Infect Dis; 1997 Mar; 24(3):498-505. PubMed ID: 9114206
[TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of cefoperazone-sulbactam combination against cefoperazone resistant clinical isolates in a Malaysian general hospital.
Lim VK; Cheong YM
Malays J Pathol; 1995 Dec; 17(2):73-6. PubMed ID: 8935129
[TBL] [Abstract][Full Text] [Related]
6. Outcome of cephalosporin treatment of bacteremia due to CTX-M-type extended-spectrum beta-lactamase-producing Escherichia coli.
Bin C; Hui W; Renyuan Z; Yongzhong N; Xiuli X; Yingchun X; Yuanjue Z; Minjun C
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):351-7. PubMed ID: 16934430
[TBL] [Abstract][Full Text] [Related]
7. [Clinical experience with the treatment of severe nosocomial infections by inhibitor-protected 3rd generation cephalosporin cefoperazone/sulbactam].
Beloborodova NV; Kuznetsova ST; Popov DA; Bachinskaia EN; Vostrikov TIu
Antibiot Khimioter; 2005; 50(4):33-40. PubMed ID: 16392338
[TBL] [Abstract][Full Text] [Related]
8. A multicentre clinical study on the injection of ceftriaxone/sulbactam compared with cefoperazone/sulbactam in the treatment of respiratory and urinary tract infections.
Xin X; Jian L; Xia X; Jia B; Huang W; Li C; Wang C; Zhou L; Sun X; Tang X; Huang Y; Zhu Y; Zhang W
Ann Clin Microbiol Antimicrob; 2013 Dec; 12():38. PubMed ID: 24321187
[TBL] [Abstract][Full Text] [Related]
9. Urinary tract infection in women over the age of 65: is age alone a marker of complication?
Grover ML; Bracamonte JD; Kanodia AK; Edwards FD; Weaver AL
J Am Board Fam Med; 2009; 22(3):266-71. PubMed ID: 19429732
[TBL] [Abstract][Full Text] [Related]
10. Risk factors for ciprofloxacin resistance among Escherichia coli strains isolated from community-acquired urinary tract infections in Turkey.
Arslan H; Azap OK; Ergönül O; Timurkaynak F;
J Antimicrob Chemother; 2005 Nov; 56(5):914-8. PubMed ID: 16174685
[TBL] [Abstract][Full Text] [Related]
11. [Comparison of efficacy between ceftriaxone and cefoperazone plus sulbactam in peri-operative treatment of acute suppurative cholangitis].
Zhou XS; Zou SQ; Dong JH; Wu WZ; Zhang YD; Zhang TL; Zeng Z; Li NF; Man GT
Zhonghua Yi Xue Za Zhi; 2004 Nov; 84(22):1879-82. PubMed ID: 15631798
[TBL] [Abstract][Full Text] [Related]
12. Antibiotic-resistant infections in primary care are symptomatic for longer and increase workload: outcomes for patients with E. coli UTIs.
Butler CC; Hillier S; Roberts Z; Dunstan F; Howard A; Palmer S
Br J Gen Pract; 2006 Sep; 56(530):686-92. PubMed ID: 16954001
[TBL] [Abstract][Full Text] [Related]
13. Cefoperazone-sulbactam for treatment of intra-abdominal infections: results from a randomized, parallel group study in India.
Chandra A; Dhar P; Dharap S; Goel A; Gupta R; Hardikar JV; Kapoor VK; Mathur AK; Modi P; Narwaria M; Ramesh MK; Ramesh H; Sastry RA; Shah S; Virk S; Sudheer OV; Sreevathsa MR; Varshney S; Kochhar P; Somasundaram S; Desai C; Schou M
Surg Infect (Larchmt); 2008 Jun; 9(3):367-76. PubMed ID: 18570578
[TBL] [Abstract][Full Text] [Related]
14. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center.
Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D
Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073
[TBL] [Abstract][Full Text] [Related]
15. A multicenter clinical study of cefoperazone.
Alix M; Arreza V; Brillantes S; Estrellado R; Gempesaw C; Monteron R; Pascasio F; Pena A; Claudio-Saniel M
Clin Ther; 1984; 6(3):344-53. PubMed ID: 6722861
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of sulbactam/cefoperazone with imipenem as empirical monotherapy for febrile granulocytopenic patients.
Winston DJ; Bartoni K; Bruckner DA; Schiller GJ; Territo MC
Clin Infect Dis; 1998 Mar; 26(3):576-83. PubMed ID: 9524826
[TBL] [Abstract][Full Text] [Related]
17. Risk factors for antibiotic-resistant Escherichia coli isolated from hospitalized patients with urinary tract infections: a prospective study.
Sotto A; De Boever CM; Fabbro-Peray P; Gouby A; Sirot D; Jourdan J
J Clin Microbiol; 2001 Feb; 39(2):438-44. PubMed ID: 11158087
[TBL] [Abstract][Full Text] [Related]
18. Multicenter clinical trials of cefoperazone in Japan.
Saito A; Ueda Y
Clin Ther; 1984; 7(1):49-59. PubMed ID: 6394129
[TBL] [Abstract][Full Text] [Related]
19. Single-blind comparison of cinoxacin and nitrofurantoin in the treatment of urinary tract infection.
Schneider RE
Clin Ther; 1982; 4(5):390-4. PubMed ID: 7039840
[TBL] [Abstract][Full Text] [Related]
20. [Multicenter research on cefoperazone efficacy and tolerance in the therapy of urinary and respiratory infections].
Paradisi F; de Crescenzo G; Ruffilli MP
Minerva Med; 1989 Jan; 80(1):43-51. PubMed ID: 2644585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
